BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

...for metastatic colorectal cancer.TARGETSFGFR - Fibroblast growth factor receptor BC Staff Treos Bio Ltd. OncoResponse Inc. BridgeBio Pharma Inc. Helsinn Group AffaMed Therapeutics (Shanghai) Co. Ltd. Helsinn...
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...AffaMed results from the October merger of AffaMed Therapeutics (Shanghai) Co. Ltd....
...Capital and Fountainhead PartnersCEO: Dayao ZhaoPatents: N/A Jeff Cranmer AffaMed Therapeutics (Shanghai) Co. Ltd. CBC...
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...By BioCentury Staff China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner...
...devices, diagnostics, providers, digital health and consumer health. BC Staff Elicio Therapeutics Inc. OncoNano Medicine Inc. Actimed Therapeutics Ltd. Tollys S.A.S. AffaMed Therapeutics (Shanghai) Co. Ltd. HighTide...
BioCentury | Jan 29, 2021
Distillery Therapeutics

VEGF-A gene editing therapy to treat wet AMD

...that antagonizes VEGF-A, in registration for wet AMD and Phase III testing for DME.Samsung Bioepis Co. Ltd., AffaMed Therapeutics (Shanghai) Co. Ltd., Biogen...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...after a high-profile debut by another of the Asian investment firm’s portfolio companies.The combination of AffaMed Therapeutics (Shanghai) Co. Ltd....
...expand into other Asian markets in the near term, and globally in the long term. Amanda Micklus AffaMed Therapeutics (Shanghai) Co. Ltd. Deals IPO merger CHS2020 EverInsight...
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...cap of HK$20.6 billion (USD$2.7 billion) at close.AffaMed licenses Kissei Parkinson’s candidateKissei Pharmaceutical Co. Ltd. (Tokyo:4547) granted AffaMed Therapeutics (Shanghai) Co. Ltd....
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...Inc. (HKSE:1530) holds rights to SB8, a biosimilar of Avastin bevacizumab, while CBC Group launched Affamed Therapeutics (Shanghai) Co. Ltd....
Items per page:
1 - 7 of 7
BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

...for metastatic colorectal cancer.TARGETSFGFR - Fibroblast growth factor receptor BC Staff Treos Bio Ltd. OncoResponse Inc. BridgeBio Pharma Inc. Helsinn Group AffaMed Therapeutics (Shanghai) Co. Ltd. Helsinn...
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...AffaMed results from the October merger of AffaMed Therapeutics (Shanghai) Co. Ltd....
...Capital and Fountainhead PartnersCEO: Dayao ZhaoPatents: N/A Jeff Cranmer AffaMed Therapeutics (Shanghai) Co. Ltd. CBC...
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...By BioCentury Staff China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner...
...devices, diagnostics, providers, digital health and consumer health. BC Staff Elicio Therapeutics Inc. OncoNano Medicine Inc. Actimed Therapeutics Ltd. Tollys S.A.S. AffaMed Therapeutics (Shanghai) Co. Ltd. HighTide...
BioCentury | Jan 29, 2021
Distillery Therapeutics

VEGF-A gene editing therapy to treat wet AMD

...that antagonizes VEGF-A, in registration for wet AMD and Phase III testing for DME.Samsung Bioepis Co. Ltd., AffaMed Therapeutics (Shanghai) Co. Ltd., Biogen...
BioCentury | Oct 16, 2020
Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

...after a high-profile debut by another of the Asian investment firm’s portfolio companies.The combination of AffaMed Therapeutics (Shanghai) Co. Ltd....
...expand into other Asian markets in the near term, and globally in the long term. Amanda Micklus AffaMed Therapeutics (Shanghai) Co. Ltd. Deals IPO merger CHS2020 EverInsight...
BioCentury | Oct 10, 2020
Product Development

Oct. 9 Quick Takes: Sobi’s Phase III miss; plus Alkermes, COVAX, Warp Speed-AZ, Lilly-Gates, Pfizer, Everest and Affamed-Kissei

...cap of HK$20.6 billion (USD$2.7 billion) at close.AffaMed licenses Kissei Parkinson’s candidateKissei Pharmaceutical Co. Ltd. (Tokyo:4547) granted AffaMed Therapeutics (Shanghai) Co. Ltd....
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...Inc. (HKSE:1530) holds rights to SB8, a biosimilar of Avastin bevacizumab, while CBC Group launched Affamed Therapeutics (Shanghai) Co. Ltd....
Items per page:
1 - 7 of 7